Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Editors Pick
    • Niramai to target...

    Niramai to target River Blindness; plans to develop AI based software

    GarimaWritten by Garima Published On 2019-04-10T09:57:15+05:30  |  Updated On 10 April 2019 9:57 AM IST
    Niramai to target River Blindness; plans to develop AI based software

    Niramai has developed a novel technique called Thermalytix, an automated diagnostic tool, which combines thermal imaging with artificial intelligence which is being used to detect early-stage breast cancer in many hospitals today.


    Bengaluru: Artificial intelligence-based Indian health-tech company Niramai recently announced that it will develop an artificial intelligence (AI)-based computer-aided software for controlling the spread of River Blindness. Niramai will leverage its innovative Thermalytix technology to detect the presence of live adult worms of Onchocerciasis which causes river blindness and significant disability.


    Thermalytix is currently being applied to early-stage breast cancer detection. This innovative non-invasive detection method is expected to help assess the efficacy of new drugs being developed to control the disease by killing the adult worms, potentially accelerating the elimination of river blindness, which has today infects ~17 million people in Africa. This project has been made possible through support from the Bill & Melinda Gates Foundation.


    Niramai has developed a novel technique called Thermalytix, an automated diagnostic tool, which combines thermal imaging with artificial intelligence which is being used to detect early-stage breast cancer in many hospitals today.


    Commenting on the research project, Dr Geetha Manjunath, CEO & CTO, Niramai, said, “We are very excited to collaborate with Gates Foundation to extend the application of our innovative technique to areas other than breast cancer. Successful completion of this research project will demonstrate a breakthrough result of Thermalytix being a new way of sensing many abnormalities in the human body in a non-invasive, radiation-free and accurate way, even beyond cancer!”


    A clinical expert collaborating with NIRAMAI, Professor Dr Christopher L King from The Centre for Global Health and Diseases, Cleveland, said, “Onchocerciasis, more commonly known as river blindness, is the world’s second leading infectious cause of blindness. NIRAMAI technology can be a valuable tool to detect infectious live worms in a non-invasive way and help with the global effort to eliminate this very disabling disease.”


    About half a million people are blind or visually impaired due to the disease which is caused by a parasitic worm living under the skin in humans, spread by black fly bites. In addition to blinding, onchocerciasis is a chronic systemic disease capable of causing extensive and disfiguring skin disease, chronic itching, musculoskeletal complaints, weight loss, alteration in host immune responses and possibly epilepsy and growth impairment. Onchocerciasis can have a considerable impact on social relationships in poorest communities. Therefore, its control and elimination have been a high priority. It has been categorized by Gates Foundation as one of the high-opportunity target diseases under the strategy to address NTDs (Neglected Tropical Diseases).


    Past awardees of Bill and Melinda Gates Foundation grant in India include Indian School of Business, International Institute of Information Technology Bangalore, Ratan Tata Trust, Dvara Research Foundation etc.


    Also Read: Desi AI based health tech startup NIRAMAI raises Rs 42.6 Crore in Series A Funding



    adult wormsAIBangaloreBill & Melinda Gates Foundationchronic diseaseGates FoundationHealthcareHealthcare NewsHealthcare news indiaNiramaiOnchocerciasisratan tata trustriver blindnessThermalytix

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Garima
    Garima

      Garima joined Medical Dialogues in the year 2017 and is currently working as a Senior Editor. She looks after all the Healthcare news pertaining to Medico-legal cases, MCI/DCI decisions, Medical Education issues, government policies as well as all the news and updates concerning Medical and Dental Colleges in India. She is a graduate from Delhi University. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751 To know about our editorial team click here

      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok